# Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:

> **NCT03573349** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 18 (estimated)

## Conditions studied

- Major Depressive Disorder
- Treatment Resistant Depression
- Bipolar Depression

## Interventions

- **DRUG:** Ketamine

## Key facts

- **NCT ID:** NCT03573349
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-03
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03573349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03573349, "Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03573349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*